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Abstract
Background: Nut consumption may reduce the risk of developing type 2 diabetes. The aim of the current study
was to measure the acute and second-meal effects of morning almond consumption and determine the
contribution of different nut fractions.
Methods: Fourteen impaired glucose tolerant (IGT) adults participated in a randomized, 5-arm, crossover design
study where whole almonds (WA), almond butter (AB), defatted almond flour (AF), almond oil (AO) or no almonds
(vehicle - V) were incorporated into a 75 g available carbohydrate-matched breakfast meal. Postprandial
concentrations of blood glucose, insulin, non-esterified free fatty acids (NEFA), glucagon-like peptide-1 (GLP-1) and
appetitive sensations were assessed after treatment breakfasts and a standard lunch.
Results: WA significantly attenuated second-meal and daylong blood glucose incremental area under the curve
(AUCI) and provided the greatest daylong feeling of fullness. AB and AO decreased blood glucose AUCI in the
morning period and daylong blood glucose AUCI was attenuated with AO. WA and AO elicited a greater second-
meal insulin response, particularly in the early postprandial phase, and concurrently suppressed the second-meal
NEFA response. GLP-1 concentrations did not vary significantly between treatments.
Conclusions: Inclusion of almonds in the breakfast meal decreased blood glucose concentrations and increased
satiety both acutely and after a second-meal in adults with IGT. The lipid component of almonds is likely
responsible for the immediate post-ingestive response, although it cannot explain the differential second-meal
response to AB versus WA and AO.
Background
The 2025 worldwide projection of IGT is 418 million
(8.1% of the adult population) [1]. Lifestyle modification,
including nutrition is the cornerstone of its manage-
ment. Macro- and micronutrients, fiber content, and
other components of the diet modulate meal-induced
insulin secretion through changes in gastrointestinal
transit time and nutrient absorption rates. Additionally,
the content of one meal has the potential to affect insu-
lin sensitivity at a second meal by altering circulating
NEFA concentrations and daylong insulin demands [2].
Almonds are a low-glycemic index (GI) food, with
high fiber, unsaturated fat and low carbohydrate
content. There is an inverse relationship between nut
consumption and risk of developing type 2 diabetes [3].
In addition, almond consumption increases satiety,
reduces cardiovascular disease risk, decreases postpran-
dial glycemia and moderates oxidative damage [4]. The
component(s) of almonds responsible for these effects
have not been determined. Almonds contain phytates
and phenolics, that confer antioxidant, anti-inflamma-
tory and lipid-lowering properties and inhibit trypsin
and amylase activity [5]. A decreased rate of nutrient
digestion may explain reported increases in satiety and
blunted blood glucose response with almond consump-
tion. Stimulation of the incretin and ileal-brake hor-
mone, GLP-1, may also contribute. Consequently,
almond consumption may be an effective dietary man-
agement tool in insulin resistant individuals who would
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rated fat [6].
I n c l u s i o no f6 0go fa l m o n d si nm e a l so fh e a l t h y
individuals decreases glycemia, insulinemia, and post-
prandial oxidative damage as measured by increased
protein thiol concentration [7]. Adding almonds (30-90 g)
to a high-GI meal results in a dose-responsive decrease in
2-hour postprandial blood glucose AUCI [8]. However,
consumption of almond oil with defatted almond flour, to
mimic a bioaccessible almond form, significantly decreased
3-hour blood glucose AUCI with no difference in insulin
response compared to when small almond particles were
consumed [9]. Similarly, increased and sustained concen-
trations of cholecystokinin (CCK) and augmented hunger
were reported with bioavailable almond oil compared to
whole almonds [10]. This suggests the bioavailability of
the lipid fraction may be responsible for decreased post-
prandial glycemia.
The present study evaluated the effects of whole
almonds, almond oil, defatted almond flour, and almond
butter on acute and second-meal postprandial blood
glucose, insulin, NEFA, and GLP-1 concentrations, as
well as satiety sensations, in IGT adults.
Methods
Eligibility criteria included: age 18-60 years; not taking
medications known to affect glycemia, sleep, or appetite;
weight stable (3 month fluctuation of <5 kg); regular
breakfast consumer (≥100 kcal ingested within 2 hours
of waking on ≥4 d/wk) o blood donation in the previous
3 months; no nut or relevant food allergy; at least one
of the following risk factors: A) self-reported family his-
tory of type 2 diabetes; B) blood pressure ≥130/85
mmHg; C) fasting blood glucose >5.6 mmol/l; or D)
waist circumference (men ≥102 cm; women ≥88 cm);
and a 2-hour blood glucose value of 7.8 and <11.1
mmol/l (i.e., IGT) [11]. Height, weight, and body com-
position were measured using a wall-mounted stadi-
ometer, a clinical scale, and bioelectrical impedence,
r e s p e c t i v e l y .A2 - h o u r ,7 5 - gram oral glucose tolerance
test (OGTT) was conducted at a second visit with parti-
cipants in an 8-10 hour fasted state. The research was
approved by the University Institutional Review Board.
One hundred-seventy individuals completed the first
screening visit, of which 132 were eligible for and com-
pleted the second screening visit. Fourteen participants
met all screening criteria and completed the full study
protocol. Calculation of power indicated that 13 indivi-
duals were necessary to det e c tac h a n g ei nb l o o dg l u -
cose of 0.35 mmol/l (a = 0.05; Power = 0.80, SD = 0.3)
[12]. Participant characteristics are shown in Table 1.
The study utilized a randomized, 5-arm, crossover,
single-blinded design. Overnight fasted (8-10 hours)
participants reported to the laboratory on 5 occasions
separated by at least one week. Menstruating female
participants completed test days within the follicular
phase of their menstrual cycle. Individuals were
requested to maintain their normal exercise, eating,
and sleeping patterns and, if taking vitamins or medi-
cations, to take them at the same time every day
before reporting for testing. Participants were also
requested to consume the same meal each evening
before reporting to the laboratory at their customary
breakfast time.
Upon arrival to the laboratory, participants were
weighed and body composition was determined. An
indwelling catheter was placed and a baseline blood
sample collected. Appetite ratings were scored on a
100 mm visual analogue scale (VAS) anchored with
descriptors of “n o ta ta l l ” and “extremely.” Next, the
participant consumed a test breakfast within 10 min-
utes that consisted of orange juice and farina [prepared
Cream of Wheat
®, B&G Foods, Inc.] containing: noth-
ing V (vehicle), whole almonds (WA), almond butter
(AB), defatted almond flour (AF) or almond oil (AO)
in randomized order. Almonds were non-pareil, dry-
roasted and added to the farina whole [provided by the
Almond Board of California (Modesto, CA)]. Almonds
and their processed forms were from the same almond
harvest. Test breakfasts were matched on available car-
bohydrate and sweetness (nutrient composition shown
in Table 2). The amount of almonds added to the cer-
eal was 42.5 grams (~33 almonds) in accord with the
Food and Drug Administration (FDA) qualified health
claim regarding daily nut intake [13]. After completion
Table 1 Participant characteristics¹
Age (y) 39.3 ± 10.9
Weight (kg) 92.6 ± 19.3
BMI (kg/m²) 33.0 ± 6.9
Body fat (%) 35.8 ± 14.0
Waist circumference (cm) 105.3 ± 16.3
Systolic blood pressure (mmHg) 130.1 ± 11.1
Diastolic blood pressure (mmHg) 82.0 ± 10.0
Fasting blood glucose (mmol/l) 5.5 ± 0.5
Fasting serum insulin (pmol/l) 88.8 ± 46.2
Total cholesterol (mmol/l) 5.42 ± 1.14
HDL-C (mmol/l) 1.18 ± 0.45
LDL-C (mmol/l) 3.16 ± 1.07
Cholesterol:HDL-C ratio 5.1 ± 1.8
Triglycerides (mmol/l) 2.80 ± 1.37
Blood glucose after 2-hour OGTT (mmol/l) 8.3 ± 0.3
QUICKI² 0. 330 ± 0.039
1N = 14 (8 M, 6 F); Mean ± SD.
2Quantitative insulin sensitivity check index = 1/[log (fasting insulin, μU/mL) +
log (fasting glucose, mg/dL)] [14].
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Page 2 of 8of the breakfast meal, palatability of the foods was
rated on a VAS (mean palatability scores are shown in
Table 3).
Blood was drawn and appetite was rated 15, 45, 60,
90, 120, 180, and 240 minutes after completion of the
test breakfast. At minute 240, participants consumed a
standard lunch within 10 minutes that consisted of a
plain white bagel, grape or strawberry jelly, and tap
water (250 ml). Palatability of the lunch was rated on a
VAS. Afternoon blood sampling and appetite scoring
occurred using the same time intervals as the morning.
Three milliliters of blood were collected in a red top
vacutainer at each draw. After clotting and centrifuga-
tion, serum was aliquoted and stored at -80°C for later
analysis of insulin, glucose, and NEFA. Four ml of blood
were collected in ice-cooled EDTA-plasma vacutainer, 40
μl DPP-IV inhibiter (Millipore, St. Charles, MO) was
added, and samples were handled according to manufac-
turer’s directions for analysis of GLP-1. All samples were
analyzed in duplicate. Insulin and glucose were measured
by electrochemiluminescence and the hexokinase
method, respectively. Sensitivity of the insulin immu-
noassay was 1.39 pmol/l (within-run coefficient of varia-
tion (CV) of 1.9%). Hexokinase sensitivity was
0.12 mmol/l (within-run CV of 0.41%). NEFA were ana-
lyzed with an enzymatic colorimetric method on an auto-
mated analyzer with a sensitivity of 0.00014 mEq/L
(within-run CV of 0.75%). GLP-1 was assessed by radio-
immunoassay. Sensitivity of the assay was 3 pmol/l
(within-run CV of 30.3%). Lipid panel assessment was
conducted by MidAmerica Clinical Laboratories, India-
napolis, IN.
Nutrient data were analyzed with the Nutrition Data
Systems for Research 2008 (University of Minnesota,
Minneapolis, MN). Statistical testing was conducted with
SPSS, Version 17.0 (SPSS Inc., Chicago, IL). Repeated
measures analysis of variance (ANOVA) was used to
explore main effects and, when appropriate, post hoc ana-
lyses were conducted with Bonferroni adjustment. Signif-
icance was set at p < 0.05. Data are represented as Mean
± SEM. Area under the Curve (AUC) with respect to
increase (I) was computed to measure concentration
change over time [14] (Formula 1) and quantitative insu-
lin sensitivity check index (QUICKI) was calculated [15].
Fasting concentrations served as baseline for daylong
(0-490 minutes) and morning responses (time 0-240
minutes) and the blood sample taken at 240 minutes
served as the baseline for afternoon responses (time
240-490 minutes).
Formula 1. Incremental Area Under the Curve
AUCI
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Where n equals the total amount of measurements, mi
equals the individual measurements, and ti equals the
time between measurements [14].
Results
Blood glucose
Fasting blood glucose concentrations were similar across
treatment arms. Mean morning glucose concentrations
were greater after consumption of V as compared to
Table 2 Test breakfast and lunch nutrient composition
Vehicle Whole Almond Almond Almond Lunch
Almond Butter Flour Oil
Energy (kcal) 347 580 580 377 537 374
Weight (g) 644.0 683.5 674.9 656.9 665.5 393.6
Fat (g) 1 22.6 22.6 1 22.6 1.6
Protein (g) 7 16 16 16 7 11.4
Dietary fiber (g) 2.1 7.1 7.1 3.6 2.1 2.8
Soluble fiber (g) 1.4 1.9 1.9 1.5 1.4 1.3
Insoluble fiber (g) 0.7 5.2 5.2 2.1 0.7 1.5
Available carbohydrate (g) 75 75 75 75 75 75
Table 3 Mean palatability scores for test foods¹
Vehicle Whole Almond Almond Almond
Almond Butter Flour Oil
Cereal 0.56 ± 0.06
a 0.61 ± 0.07
a 0.57 ± 0.07
a 0.52 ± 0.08
a, b 0.37 ± 0.08
b
Orange Juice 0.75 ± 0.05 0.78 ± 0.05 0.73 ± 0.06 0.77 ± 0.04 0.73 ± 0.05
Bagel 0.59 ± 0.06 0.64 ± 0.06 0.58 ± 0.04 0.66 ± 0.05 0.65 ± 0.05
¹ Different superscripts indicate significant difference within the meal period (P < 0.05); values represent the score on a 100 mm visual analog scale.
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greater with AB than all others (P < 0.002). Mean day-
long blood glucose change from baseline was lower after
consumption of WA compared to AB, AF and V (P <
0.02) (Figure 1C). Daylong blood glucose response was
lower with WA compared to V (P < 0.05).
V resulted in a greater blood glucose peak than AB
and AO (P < 0.001) with a trend in comparison with
WA (P = 0.069). The post-lunch peak was greater with
AB compared to WA, AF, and V (P < 0.02) and
approached significance compared to AO (P = 0.055).
AUCI was less in WA compared to AB, AF, and V and
greater in AB versus AO (P < 0.05) (Figure 2). Morning
AUCI with AO was lower than AF and V (P < 0.01) and
WA was lower than V (P < 0.04). Afternoon AUCI was
lower after WA compared to AB and AO (P < 0.04).
Serum Insulin and Insulin Sensitivity
Fasting insulin was greater in WA compared to V and
AF; AO was greater than AF and AB (P < 0.05). The
change of insulin from baseline in the morning and over
the test day did not differ between treatments. The
afternoon insulin response to V was less than WA, AB,
and AO, whereas both AO and WA were greater than
AF (P < 0.04) (Figure 1B). No differences in absolute
peak concentrations occurred in the morning, but the
afternoon peak was greater with WA compared to AF
and AO compared to AF and V (P < 0.02).
AUCI was greater in AB versus V (P < 0.03) (Figure 2).
Postprandial breakfast AUCI for AB was greater than V
(P < 0.04). WA postprandial lunch AUCI was greater than
AF and V (P < 0.05), and AF was less than AO (P < 0.01).
W AQ U I C K Iw a sl e s st h a nt h a tf o rA Ba n dA F( P<
0.05) and trended lower compared to V (P = 0.068). AO
QUICKI was less than AB and AF (P < 0.02).
Nefa
Fasting NEFA concentrations with AF were lower than AB
and V (P < 0.02) and approached significance compared to
AO (P = 0.06). Morning NEFA concentrations were
greater with AB than all others (P < 0.05). AB was greater
than V in the afternoon (P < 0.01). Daylong concentrations
were lower with AF compared to both AB and AO (P <
0.03) and V was less than AB (P < 0.001) (Figure 1A).
Absolute peak response in both time periods was greater
in AB than in AF (P < 0.05). WA morning peak concentra-
tion tended to be lower than AB (P = 0.053).
Morning and daylong NEFA AUCI were less sup-
pressed in AF versus V (P < 0.03) (Figure 2). NEFA
AUCI following WA trended toward greater suppression
than V in the morning and over the day (P = 0.067).
Afternoon AUCI was less suppressed in AB versus WA
and AO (P < 0.05).
Plasma GLP-1
Fasting GLP-1 concentrations were similar between vis-
its (19.99 ± 1.28 pmol/l). There were no significant
treatment effects.
Appetite Ratings
No differences in fasting or treatment-related hunger
ratings occurred. Daylongf u l l n e s sr a t i n g sw e r e
Figure 1 A) Daylong NEFA concentrations as change from
baseline; B) Daylong insulin concentrations as change from
baseline; C) Daylong glucose concentrations as change from
baseline (*P < 0.05). black circles = WA (whole almonds); white
circles = AB (almond butter); black triangles = AF (almond flour);
white triangles = AO (almond oil); white squares = V (vehicle).
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(P < 0.04) and in AB compared to AF and V (P < 0.01)
(Figure 3). Fullness was greater in the morning with
WA versus AF and AO and in AB versus AF (P < 0.04),
with WA trending higher than V (P = 0.058). Afternoon
fullness ratings were greater in WA compared to AF
and V (P < 0.001), lower in AF versus AB (P < 0.01)
and lower in V compared to AB and AO (P < 0.03).
Palatability
Mean palatability was lower for the farina containing
AO compared to WA, AB, and V (P < 0.04), but no
sample rated in the lower third of the hedonic scale
(Table 3).
Body Weight and Composition
There was no difference in body weight, BMI, or any
measures of body composition across treatment visits.
Discussion
The aims of this study included confirmation that nut
consumption improves the metabolic profile with
respect to diabetes risk; determination of the relative
contributions of different almond fractions on these
indices and whether acute post-prandial benefits
translate to improved insulin sensitivity at a subse-
quent eating event (second-meal effect). To enhance
the ecological validity of the work, whole almonds
were included to explore effects with natural mastica-
tion and the quantity of almonds included in the test
meal corresponded to the recommended intake level
in the FDA approved qualified health claim for nuts
[13].
Figure 3 Area plot of fullness ratings in millimeters from the
“not at all anchor” of a 100 mm visual analog scale. (WA =
whole almond; AB = almond butter; AF = almond flour; AO =
almond oil; V = vehicle).
Figure 2 A) NEFA AUCI for the day (time 0-490 min), morning
period (first-meal; time 0-240 min.), and afternoon AUCI
(second-meal; time 240-490 min.); B) Insulin AUCI ; C) Glucose
AUCI. Different lowercase letters indicate significant differences
within the response period for each measurement (P < 0.05).
(solid black = WA (whole almonds); vertical lines = AB (almond
butter); vertical and horizontal lines = AF (almond flour); diagonal
lines = AO (almond oil); solid white = V (vehicle)).
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concentrations with WA and AO led to lower QUICKI
values and therefore less calculated insulin sensitivity.
Due to its correlation with the hyperinsulinemic euglyce-
mic clamp [15], QUICKI is the preferred method for
quantifying insulin sensitivity in populations with per-
turbed insulin sensitivity. Despite higher baseline insulin
concentrations, consumption of WA and AO decreased
morning blood glucose AUCI compared to V. Postpran-
dial breakfast insulin and NEFA AUCI were not greater
after consumption of WA and AO suggestive of greater
insulin sensitivity (e.g. the decreased blood glucose AUCI
was not determined by a concurrent increased insulin
response). Similarly, consumption of 60 g of almonds
with white bread decreased 2-hour blood glucose and
insulin AUCI in healthy individuals compared to a con-
trol meal [7]. Moreover, in healthy men, bioaccessible
almond composition produced a lower 3-hour blood glu-
cose response with no significant difference in the insulin
or NEFA response [9]. Larger almond particles did not
produce the same effect. Previous data from our labora-
tory did not find a clear relationship between amount of
almond chewing (predefined number of chews) and
changes in glucose and insulin concentrations in a group
of healthy participants [16]. Discrepancies between stu-
dies may be due to differences in almond particle sizes
(e.g., naturally masticated versus predefined) which could
alter nutrient bioaccessibility.
In contrast to lipid-containing treatments, the treat-
ments with little fat (V and AF) produced the largest
immediate postprandial glucose responses. The role of
fat in decelerating gastric emptying may be partly
responsible [17]. Although the AF treatment contained
polyphenolic compounds, there was no evidence of
impairment of starch digestion in the current study as
has been previously reported [18]. NEFA concentrations
after consumption of AF were lower than V in the
morning postprandial period without differences in insu-
lin concentrations, indicating a slight improvement in
NEFA suppression. In comparison, no difference in
NEFA concentrations between the combination of AF
and AO, large almond particles, and control sunflower
oil [9] suggests minimal benefit to the presence of the
defatted flour fraction on metabolic risk outcomes.
One study suggested the NEFA concentration 4 hours
after a test breakfast accounted for ~50% of the variabil-
ity in the glycemic response to a standard lunch [19].
We found no significant difference at this time point
and do not confirm that NEFA concentrations explain
second-meal metabolic differences. However, AB
resulted in the lowest overall degree of NEFA suppres-
sion in the morning period and was associated with the
greatest blood glucose response to the standard lunch.
The overall NEFA response in the period before the
meal may be a stronger determinant of the second-meal
glycemic response than the concentration immediately
preceding the second meal. Additionally, no differences
were observed in glucose, insulin, or GLP-1 concentra-
tions at 4 hours after the test breakfast, suggesting other
determinants of second-meal effects. While the mechan-
ism remains uncertain, this trial confirms the phenom-
enon. Prior work revealed that inclusion of slowly
digestible carbohydrate (e.g., lentils) in a breakfast meal
reduced the glucose response after lunch [20]. We show
that inclusion of a high unsaturated fat load with break-
fast is also effective. Together, these data support the
efficacy of dietary moderation of carbohydrate absorp-
tion kinetics from a morning meal for extended glyce-
mic control in populations at risk for or with type 2
diabetes.
The high unsaturated fatty acid composition of
almonds may account for the blunted glucose concen-
trations noted in the postprandial period. Acute con-
sumption of PUFA and MUFA decreases postprandial
glucose AUCI without altering insulin concentrations
[21] due to increased efficiency of insulin receptor sig-
naling and increased glycemic control through stimula-
tion of GLP-1 [6]. Although no significant treatment
effects were detected in GLP-1 concentrations, WA and
AO led to an overall greater and sustained GLP-1
response that may have contributed to blunted second-
meal blood glucose concentrations [22] and modified
satiety [23].
The role of almond lipid bioavailability in triggering
the release of gut peptides and contributing to energy
balance is complicated by differences in the metabolic
profiles following WA and AO versus AB consumption.
Previous research in healthy participants showed lower
breakfast and increased afternoon blood glucose AUCI
after consumption of a standard lunch when peanut
butter or butter was consumed in a mixed breakfast
meal [24]. Our data show this similar afternoon rebound
with consumption of AB in the breakfast meal, which
cannot be attributed
solely to the lipid component. Additionally, in vitro
gastric and duodenal digestion modeling found greater
duodenal lipid digestion in finely ground almond parti-
cles compared to defatted finely ground almonds with
almond oil added back, suggesting that differential dis-
persion of the lipid (e.g. different surface areas of the
lipid droplets) may determine bioaccessibility [25].
Altering the physical form of nuts may have unexpected
metabolic effects that warrant further investigation.
Differences in fullness were not likely due to variations
in the macronutrient content of the test foods. All pro-
vided 75 g of available carbohydrate and the treatments
matched on protein, fat, total and soluble fiber, and
energy led to variable satiety responses. The cognitive
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orosensory stimulation from chewing may be responsi-
ble for satiety effects [26]. Lipid consumed in oil form
previously induced a greater and sustained CCK
response and greater satiety in women versus consump-
tion of WA [10], a finding not confirmed in the current
study.
An unavoidable limitation of the current study was
that breakfast meals were not matched on energy,
volume, or macronutrient composition. Due to the
study design, available carbohydrate (the main determi-
nant of GI) was standardized between all treatments and
macronutrients were matched when possible. The sub-
jective palatability of the treatments was not consistent,
with AO considered significantly less desirable than all
other treatments except for AF. However, post hoc cov-
ariate analysis did not reveal palatability significantly
altered results. Additionally, participants were instructed
to consume the same meal before reporting for each
visit, although significant differences were found. Fewer
calories were consumed the night before WA compared
to V (~200 kcal) and a lower percent of calories from
carbohydrate was consumed the night before AO com-
pared to AB (~5%). The extent to which these differ-
ences can explain postprandial breakfast responses is
unknown. Greatly altering the GI of a dinner may pro-
duce a varied response after a breakfast meal, but the
absorptive characteristics between the evening meals
consumed before test days in the current study were
unlikely so drastically different as those that have pre-
viously been shown to produce carry-over effects to the
breakfast meal [27]. The possibility exists that differ-
ences in dietary intake may also be an artifact of the dif-
ficulty of accurately assessing dietary intake and single
meal reporting precludes the ability to employ calcula-
tions such as the Goldberg cut-off to determine plausi-
bility of reported intake. Nonetheless, the macronutrient
and energy intake data appear to fall within normal
ranges (49-54% energy from carbohydrate, 28-33%
energy from fat, 18-19% energy from protein, and ~30%
of mean estimated daily energy requirements).
In summary, inclusion of almonds in the breakfast
meal of IGT adults decreased blood glucose concentra-
tions and increased satiety acutely and after a second
meal. The lipid component of the almond appears to be
largely responsible for the immediate post-ingestive
response, although it cannot account for the second-
meal response. Overall, daylong glucose, insulin and
NEFA concentrations were attenuated in the WA and
AO treatments, indicating an improved hormonal pro-
file with their consumption. Importantly, the absolute
magnitude of the blood glucose-lowering response
equals that achieved with acute administration of acar-
bose in individuals with IGT [28], suggesting the
physiological relevance and applicability of the current
findings.
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